Scinai Immunotherapeutics has reported impressive financial results for the first nine months of 2025, showcasing growth in CDMO services and advancing its innovative NanoAbs pipeline.

Scinai Immunotherapeutics will showcase its advanced inflammation and immunology pipeline during BIO-Europe Spring 2025 in Milan, enhancing visibility and investor engagement.

Scinai Immunotherapeutics is set to engage with investors and pharma leaders at major upcoming US conferences. Key executives will seek strategic partnerships and showcase their innovative nanoAbs.

Revenues for the nine months ended September 30, 2025 were $1,049 thousand, compared to $452 thousand for the nine months ended September 30, 2024. The increase reflects continued expansion of Scinai Bioservices, including contributions from the Company's U.S. subsidiary. R&D expenses for the nine months ended September 30, 2025 amounted to $1,799...

Scinai leadership team presents innovative NanoAbs pipeline and premium CDMO services at BIO-Europe Spring 2025. Schedule one-on-one meetings with executives in Milan.

Scinai's leadership team will showcase NanoAbs technology and CDMO services at three prestigious US healthcare conferences in January, meeting investors and potential partners.